Tools to Address the Opioid Epidemic
If you have questions, please contact Norma Haskins at 515-283-9343.
Physicians, healthcare professionals, quality improvement managers, and other interested entities across all healthcare settings and IHC programs including HIIN, TCPI and SIM.
There are several tools available to address the opioid epidemic. This session will focus on tools such as the prescription drug monitoring program, medication disposal programs, naloxone prescribing and dispense, and comfort resources to assist providers and patients with addressing the opioid crisis.
- Examine multiple tools that address the opioid epidemic including the prescription drug monitoring programs, medical disposal programs, and naloxone prescribing and dispensing.
- Discuss the Opioid Guardianship Project, state opioid guidance documents and comfort resources.
Danna Droz, RPh, JD, is a registered pharmacist licensed in Kentucky and Ohio. She is a graduate of the Brandeis School of Law at the University of Louisville and a member of the Kentucky and Ohio Bars. Currently Droz is the Prescription Monitoring Program (PMP) Liaison for the National Association of Boards of Pharmacy (NABP). She works with state PMPs to enhance their ability to work together and utilize NABP tools to complement the state programs. Droz is a frequent presenter on prescription monitoring programs and drug law topics including pharmacy drug law, drug law for practitioners and drug diversion. She also consults with states that are considering modifications to a prescription monitoring program.
Eileen Lewalski, PharmD, JD, joined NABP as the professional affairs manager in 2007 and functions now as the pharmacy affairs senior manager where she assists with developing and implementing Association policy. She is also an adjunct professor at the Midwestern University College of Pharmacy where she teaches Pharmacy Law and Ethics. Prior to joining NABP, Lewalski was a health-related prosecutions attorney for the Illinois Department of Financial and Professional Regulation. She also practiced pharmacy at Walgreen Company for approximately 15 years. She earned her doctor of pharmacy degree from the University of Illinois at Chicago College of Pharmacy and her doctor of jurisprudence degree from John Marshall Law School in Chicago, IL.
Krystalyn Weaver, PharmD, is the vice president of policy and operations for the National Alliance of State Pharmacy Associations (NASPA). In this role, she works with the state pharmacy associations and NASPA’s national partners to track, trend, and communicate health care policy information and best practices. She earned her bachelor’s and doctorate of pharmacy degrees from The University of Toledo in Toledo, Ohio. Krystalyn is currently enrolled in a part-time law program at George Mason University’s Antonin Scalia Law School.
Relevant to the content of this educational activity, the following individuals have no conflict of interests with commercial interests to disclose.
- Ellyn Cottingham, Planning Committee Member
- Nicky Carlson, Planning Committee Member
- Sarah Derr, Planning Committee Member
- Eileen Lewalski, PharmD, JD, Speaker
- Krystalyn Weaver, PharmD, Speaker
Relevant to the content of this educational activity, the following individual(s) have a conflict of interest with commercial interests to disclose.
- Danna Droz, RPh, JD, Speaker - Self-managed stock holder with GlaxoSmithKline
Continuing Education Credit
- DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this program for a maximum of 1.0 AOA Category 2-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
- MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS) through the joint providership of Des Moines University (DMU) and the Iowa Healthcare Collaborative. DMU is accredited by IMS to provide continuing medical education for physicians. DMU designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- Other Health Professionals: This live activity is designated for 1.0 AMA PRA Category 1 Credit(s)TM.
No commercial interest company provided financial support for this continuing education activity.
Everyone in a position to control the content of this educational activity will disclose to the CME provider and to attendees all relevant financial relationships with any commercial interest. They will also disclose if any pharmaceuticals or medical procedures and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). Determination of educational content and the selection of speakers is the responsibility of the activity director. Firms providing financial support did not have input in these areas. The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The content of each presentation does not necessarily reflect the views of Des Moines University.
- 1.00 AMA PRA Category 1 Credits™
- 1.00 AOA Category 2A
- 1.00 CE Contact Hour(s)